sodium (1S)-1-(4,5-diphenyloxazol-2-yl)methyloxy-5-carboxymethoxy-1,2,3,4-tetrahydronaphthalene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: sodium (1S)-1-(4,5-diphenyloxazol-2-yl)methyloxy-5-carboxymethoxy-1,2,3,4-tetrahydronaphthalene
• 英文别名: sodium;2-[[(5S)-5-[(4,5-diphenyl-1,3-oxazol-2-yl)methoxy]-5,6,7,8-tetrahydronaphthalen-1-yl]oxy]acetate
• 化学式: C₂₈H₂₄NO₅*Na
• 分子量: 477.492
• InChiKey: IJVCZJDMSSBNCI-BQAIUKQQSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.74
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  84.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-(bromomethyl)-4,5-diphenyloxazole 在 sodium hydroxide 、 正丁基锂 、 四丁基氟化铵 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 sodium (1S)-1-(4,5-diphenyloxazol-2-yl)methyloxy-5-carboxymethoxy-1,2,3,4-tetrahydronaphthalene
  参考文献：
  名称：

  Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: Orally active prostacyclin mimetics. Part 2

  摘要：

  Synthetic and biological evaluation of novel diphenyloxazole derivatives containing a pyrrolidine ring, as a prostacyclin mimetic without the PG skeleton, are described. Asymmetric reduction of a ketone using a chiral Ru complex and reductive amination by NaBH4 produces four isomers of the tetrahydronaphthalene ring and the pyrrolidine ring with high stereoselectivity. FR193262 (4), (R,R)-diphenyloxazolyl pyrrolidine derivative, displays high potency and agonist efficacy at the IP receptor and has good bioavailability in rats and dogs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.042

文献信息

• 4,5-dipheny-oxazole derivatives and their use as platelet aggregation inhibitors
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1213285A3

  公开（公告）日：2002-07-03

  Heterocyclic compounds of the formula:    whereinR1 is carboxy or esterified carboxy,R2 and R3 are phenyl or (C1-C6)alkylphenyl,A1 is (C1-C6)alkylene, andn is 0 or 1, for the treatment or prevention of arterial obstruction, hepatitis, hepatic insufficiency, restenosis after percutaneous transluminal coronary angioplasty, arteriosclerosis, cerebrovascular disease or ischemic heart disease.

  公式为的杂环化合物：其中R1是羧基或酯化羧基，R2和R3是苯基或（C1-C6）烷基苯基，A1是（C1-C6）亚烷基，n为0或1，用于治疗或预防动脉阻塞、肝炎、肝功能不全、经皮冠状动脉腔内成形术后再狭窄、动脉硬化、脑血管病或缺血性心脏病。
• Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: Orally active prostacyclin mimetics. Part 2
  作者：Kouji Hattori、Osamu Okitsu、Seiichiro Tabuchi、Kiyoshi Taniguchi、Mie Nishio、Satoshi Koyama、Jiro Seki、Kazuo Sakane

  DOI：10.1016/j.bmcl.2005.04.042

  日期：2005.7

  Synthetic and biological evaluation of novel diphenyloxazole derivatives containing a pyrrolidine ring, as a prostacyclin mimetic without the PG skeleton, are described. Asymmetric reduction of a ketone using a chiral Ru complex and reductive amination by NaBH4 produces four isomers of the tetrahydronaphthalene ring and the pyrrolidine ring with high stereoselectivity. FR193262 (4), (R,R)-diphenyloxazolyl pyrrolidine derivative, displays high potency and agonist efficacy at the IP receptor and has good bioavailability in rats and dogs. (c) 2005 Elsevier Ltd. All rights reserved.